hero image

What happened?

Ranitidine is a drug used for treating various gastric disorders including peptic ulcer disease, gastroesophageal reflux disease, Zollinger–Ellison syndrome and heartburn.

Ranitidine was developed in the 1970s and commercialized in 1981. It was the second H2 blocker to hit the market in many countries. By 1988 it was the world’s top selling drug with sales over $1 billion. Generics arrived in 1987 after the patent ran out in the US and it went over the counter (OTC) starting in 2014. The ranitidine market was valued at over $400 million in 2018. It is available in several doses and routes of administration.

Ranitidine is nearly 40 years old and the safety profile has been mild and has been felt to be well established. Until it wasn’t.

On September 13, 2019 FDA announced it was reviewing the safety of ranitidine. On September 23, Dr. Janet Woodcock head of FDA’s CDER announced that an impurity called N-nitrosodimethylamine (NDMA) was found at low levels in some ranitidine samples tested. NDMA is classified as a probable human carcinogen and is a known environmental contaminant found in water and food.

This followed a major recall of the anti-hypertensive valsartan due to NDMA found in some samples. Hence NDMA is a focus of interest in other products.

Starting on September 24, several pharma companies and retailers stopped selling ranitidine or voluntarily withdrew the products from the market.

The amounts found in the drugs were low and FDA stated: “Although NDMA may cause harm in large amounts, the levels the FDA is finding in ranitidine from preliminary tests barely exceed amounts you might expect to find in common foods.” FDA continued the evaluation of NDMA.

On October 2, FDA noted that the testing method for NDMA in valsartan involved heating the material which, itself, could produce NDMA. The agency requested that companies test ranitidine using a different methodology (which FDA described) that did not involve heating. FDA added that, using its limited testing of ranitidine using the preferred methodology, they found unacceptable levels of NDMA.

Three weeks later FDA issued another more readily available method that could be used for testing for NDMA in ranitidine. Several other companies recalled all prescription and OTC ranitidine.

FDA suggested that patients speak to their health care providers about whether to stop ranitidine or switch to alternative therapies. For OTC patients, FDA advise considering the use of other H2 blockers or PPI’s which do not contain NDMA if they wished to change. The FDA has a website which it frequently is updating with the latest information.

The EMA has also reacted. In mid-September they sent out a notice to marketing authorization holders (MAHs) to take steps to investigate their products that might contain NDMA and other nitrosamines. https://www.ema.europa.eu/en/documents/referral/nitrosamines-emea-h-a53-1490-information-nitrosamines-marketing-authorisation-holders_en.pdf

They requested: the companies to:

Not surprisingly, many countries and companies around the world began withdrawing ranitidine from their markets.

Questions remain however. There is some controversy over whether the NDMA is a contaminant or a breakdown product of an unstable molecule. In other words, does Ranitidine break down into NDMA? See: https://www.medpagetoday.com/gastroenterology/gerd/82550

In addition, it is not clear yet whether the levels found are clinically significant.

So this issue is ongoing but it is likely that ranitidine will be off the market or, if still on the market, rarely used. Drugs in this situation rarely come back even if exoneration occurs. Since there are many alternatives to ranitidine (other H2 blockers and PPIs) without NDMA, there seems little reason to continue use of ranitidine.

What do we learn?

There are several important points to take from this still ongoing signal and safety issue.

Safety issues can occur at anytime during the lifecycle of a drug. There are many reasons for this including other drugs (legal or illicit) that interfere or interact, new routes of administration, new populations taking the drug, increases in patients using the drug (e.g. after going OTC), new diseases “popping up”, new diagnostic modalities allowing the discovery of previously unthought-of contaminants, toxins, changes in manufacture, new excipients and additives, quality changes etc. and other difficult to discern causes.

The chart below illustrates this point very dramatically. This chart was prepared by FDA and shows safety-related drug label changes as a function of time after first introduction of the drug to the US market. It covers label changes made from October 2002 to August 2005 (about 33 months) for 1601 drugs. On the x-axis is the time in years post-approval of the drug and on the y-axis the number of label changes. Several points are noteworthy:

Several conclusions can be drawn here.

So what happened with ranitidine? The investigations are ongoing, but several things seem to be evident now.

There are also some longer-term implications. It seems that the discovery of this issue in valsartan triggered the look at ranitidine. The EMA and presumably the FDA is looking at other drugs that might contain NDMA. Will we now see several other drugs in this situation? This is not a public health problem for ranitidine as several other alternatives without any NDMA. Will we now see several other drugs in this situation? This is not a public health problem for ranitidine as several other alternatives without any NDMA issues exist for patients. But what about drugs that have no adequate replacements? Are we opening a can of worms?

Finally, from a commercial point of view, it is highly unlikely that ranitidine, even if kept on the market will ever be widely used again. Even if the drug is somehow “totally exonerated” few will use it if good alternatives are available. One also expects lawsuits to start.

So, once again we see that drug safety and pharmacovigilance are fascinating, frightening and fraught fields.

Related Articles